Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?

The Prostate Pub Date : 2022-04-01 Epub Date: 2022-01-11 DOI:10.1002/pros.24301
Yilin Cao, Daniel Y Song, Curtiland Deville, Theodore L DeWeese, Stephen Greco, Phuoc T Tran, Matthew P Deek
{"title":"Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?","authors":"Yilin Cao,&nbsp;Daniel Y Song,&nbsp;Curtiland Deville,&nbsp;Theodore L DeWeese,&nbsp;Stephen Greco,&nbsp;Phuoc T Tran,&nbsp;Matthew P Deek","doi":"10.1002/pros.24301","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>A subset of patients with high-risk pathological features at radical prostatectomy recur with oligometastatic disease. The aim of this study is to investigate the rate of prostate bed recurrence, with or without history of prostate bed irradiation (PBRT), in oligometastatic prostate cancer (OMPC) patients after metastasis-directed therapy (MDT).</p><p><strong>Methods: </strong>We performed a retrospective analysis of hormone-sensitive OMPC patients treated initially with curative-intent radical prostatectomy followed by disease recurrence and metastasis-directed stereotactic ablative radiotherapy (SABR) at our institution. Prostate bed recurrence rates were compared between patients who had PBRT at any point (i.e., before oligometastatic diagnosis or concurrently with MDT) versus those with no history of PBRT.</p><p><strong>Results: </strong>Seventy-seven patients were included, and 68.8% had received PBRT. There were no significant differences in baseline characteristics between those who had received and had not received PBRT. There were five prostate bed recurrences following MDT, specifically with a 24-month cumulative incidence of 30.4% in patients who did not have PBRT and 2.4% in those who did (p = 0.03). Three of the five recurrences were isolated to the prostate bed at time of recurrence.</p><p><strong>Conclusions: </strong>Relapsed oligometastatic prostate cancer patients who have not received maximal local consolidative therapy to the prostate bed may have higher rates of local failure. Prospective studies are warranted investigating when prostate bed irradiation should be considered for patients after radical prostatectomy who ultimately have oligometastatic prostate cancer.</p>","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":" ","pages":"551-555"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.24301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: A subset of patients with high-risk pathological features at radical prostatectomy recur with oligometastatic disease. The aim of this study is to investigate the rate of prostate bed recurrence, with or without history of prostate bed irradiation (PBRT), in oligometastatic prostate cancer (OMPC) patients after metastasis-directed therapy (MDT).

Methods: We performed a retrospective analysis of hormone-sensitive OMPC patients treated initially with curative-intent radical prostatectomy followed by disease recurrence and metastasis-directed stereotactic ablative radiotherapy (SABR) at our institution. Prostate bed recurrence rates were compared between patients who had PBRT at any point (i.e., before oligometastatic diagnosis or concurrently with MDT) versus those with no history of PBRT.

Results: Seventy-seven patients were included, and 68.8% had received PBRT. There were no significant differences in baseline characteristics between those who had received and had not received PBRT. There were five prostate bed recurrences following MDT, specifically with a 24-month cumulative incidence of 30.4% in patients who did not have PBRT and 2.4% in those who did (p = 0.03). Three of the five recurrences were isolated to the prostate bed at time of recurrence.

Conclusions: Relapsed oligometastatic prostate cancer patients who have not received maximal local consolidative therapy to the prostate bed may have higher rates of local failure. Prospective studies are warranted investigating when prostate bed irradiation should be considered for patients after radical prostatectomy who ultimately have oligometastatic prostate cancer.

复发性少转移性前列腺癌的前列腺床放射治疗:我们应该多全面?
目的:一组在根治性前列腺切除术中具有高危病理特征的患者复发为少转移性疾病。本研究的目的是调查低转移性前列腺癌(OMPC)患者在接受转移导向治疗(MDT)后,有或没有前列腺床照射(PBRT)史的前列腺床复发率。方法:我们对激素敏感的OMPC患者进行了回顾性分析,这些患者最初接受治疗意图根治性前列腺切除术,随后疾病复发和转移定向立体定向消融放疗(SABR)。前列腺床复发率比较了在任何时间(即在少转移诊断前或同时进行MDT)有PBRT的患者与没有PBRT病史的患者之间的差异。结果:纳入77例患者,68.8%的患者接受了PBRT治疗。接受和未接受PBRT治疗的患者在基线特征上没有显著差异。MDT后有5例前列腺床复发,特别是未接受PBRT的患者24个月累计发病率为30.4%,接受PBRT的患者为2.4% (p = 0.03)。5例复发中的3例在复发时被分离到前列腺床。结论:未接受前列腺床最大局部巩固治疗的复发少转移性前列腺癌患者可能有较高的局部失败率。对于根治性前列腺切除术后最终患有少转移性前列腺癌的患者,何时应考虑前列腺床照射是有必要进行前瞻性研究的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书